TLRY
TLRY
NASDAQ · Pharmaceuticals

Tilray Brands Inc

$6.16
-0.08 (-1.28%)
As of May 9, 1:41 AM ET ·
Financial Highlights (FY 2026)
Revenue
99.59M
Net Income
-265,146,939
Gross Margin
29.3%
Profit Margin
-266.3%
Rev Growth
+9.3%
D/E Ratio
0.20
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 29.3% 29.3% 58.9% 58.9%
Operating Margin -277.9% -250.1% 36.6% 37.4%
Profit Margin -266.3% -252.9% 27.4% 25.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 99.59M 91.08M 180.40M 169.99M
Gross Profit 29.17M 26.68M 106.25M 100.12M
Operating Income -276,784,886 -227,827,325 66.09M 63.51M
Net Income -265,146,939 -218,247,891 49.45M 42.44M
Gross Margin 29.3% 29.3% 58.9% 58.9%
Operating Margin -277.9% -250.1% 36.6% 37.4%
Profit Margin -266.3% -252.9% 27.4% 25.0%
Rev Growth +9.3% +9.3% -1.4% +19.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 55.49M 55.49M 368.43M 383.92M
Total Equity 277.01M 277.01M 614.67M 608.97M
D/E Ratio 0.20 0.20 0.60 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -262,663,987 -228,215,463 94.91M 94.57M
Free Cash Flow 60.57M 46.11M